|

GM-CSF Clinical Trials

5 actively recruiting trials across 3 locations

Also known as: Granulocyte-Macrophage Colony-Stimulating Factor, Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor, Sargramostim

Other2 trials

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Phase 2
The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy
Phase 2

Los Angeles, California1 trial

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Children's Hospital Los Angeles

Phase 2

Boston, Massachusetts1 trial

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Beth Israel Deaconess Medical Center

Phase 1

New York, New York1 trial

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.